Recognized industry leader brings deep finance and operational experience to Tryp board SAN DIEGO, Feb. 22, 2022 /CNW/ – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company“), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, is pleased to announce that Mr. David L. Tousley, CPA, MBA, has been appointed as a new…


Previous articlePT331 – Julie Zukof & Dr. Michelle Weiner – Psychedelic Women, Coaching, and Ketamine For Fibromyalgia
Next articleDiamond Therapeutics Achieves Last Patient Last Visit in Clinical Trial of Low-Dose Psilocybin